Cliavist in Infectious and Degenerative Diseases of the Spine

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by University Hospital, Strasbourg, France.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT00372281
First received: September 4, 2006
Last updated: February 24, 2009
Last verified: February 2009

September 4, 2006
February 24, 2009
March 2007
August 2009   (final data collection date for primary outcome measure)
  • First MRI: performed immediately after gadolinium administration [ Time Frame: immediately after gadolinium administration ] [ Designated as safety issue: No ]
  • Second MRI: performed 24 hours after cliavist administration [ Time Frame: 24 hours after cliavist administration ] [ Designated as safety issue: No ]
  • First MRI: performed immediately after gadolinium administration
  • Second MRI: performed 24 hours after cliavist administration
Complete list of historical versions of study NCT00372281 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Cliavist in Infectious and Degenerative Diseases of the Spine
Comparison of Cliavist Enhancement in Infectious and Degenerative Diseases of the Spine

USPIO contrast enhancement results from intracellular trapping of the iron particles in reactive cells, especially macrophages. 17FDG-PET studies have demonstrated that macrophages are present in spine infectious diseases but are absent in spine degenerative diseases. The aim of this work is to compare the enhancement induced by CLIAVIST in both diseases. The absence of macrophages in degenerative lesions should help to differentiate them from infectious lesions, who should present contrast enhancement in relation to the presence of macrophages.

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Spine Infection
Drug: Cliavist
Injection of 0,9 mL (weight < 60kg) or 1,4 mL (weight > 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
Experimental: Cliavist
Intervention: Drug: Cliavist
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
December 2009
August 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • spine infection or spine degenerative disease
  • patient agreement obtained

Exclusion Criteria:

  • pregnancy
  • MRI contra-indications
  • cliavist contra-indication
  • dextran allergy
Both
18 Years and older
No
Contact: Jean-Louis Dietemann, MD (33) 3 88127888 jean-louis.dietemann@chru-strasbourg.fr
Contact: Stéphane Kremer, MD (33) 3 88127888 stephane.kremer@chru-strasbourg.fr
France
 
NCT00372281
3780
No
Christine GEILLER, Direction de la Recherche Clinique et de l'Innovation - Hôpitaux Universitaires de Strasbourg
University Hospital, Strasbourg, France
Not Provided
Study Director: Jean-Louis Dietemann, MD Hôpitaux Universitaires de Strasbourg
University Hospital, Strasbourg, France
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP